

Understanding Gastric Problems in Pregnancy

Nazmul MHM¹, Kohinoor Pervin², Mohammed Shahjahan Kabir³, Lubna Shirin⁴, Rajesh Thangarajan³, Jasvinder K¹, Sergey Gupalo⁵, Saeid Reza Doustjalali⁶, Fazlul MKK⁷, Sivasuthan Letchumanan⁸, Negar Shafiei Sabet⁶

¹Graduate School of Medicine, Perdana University, Damansara Heights, 50490 Kuala Lumpur, Malaysia

²Faculty of Medicine, AIMST University, Bedong, 08100, Kedah, Malaysia

³International Medical School, Management and Science University, Shah Alam 40100, Selangor, Malaysia

⁴Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Jalan Hospital, Sungai Buloh, 47000 Selangor, Malaysia

⁵Saint James School of Medicine Anguilla, The Quarter 2640, Anguilla

⁶Faculty of Medicine, SEGi University, Kota Damansara, Selangor, Malaysia

⁷Faculty of Industrial Sciences & Technology, Universiti Malaysia Pahang, 26300 Gambang, Kuantan, Pahang, Malaysia

⁸Faculty of T & CM, University of Cyberjaya, 63000 Cyberjaya, Selangor, Malaysia

Abstract

Gastric problems are common during pregnancy and can significantly impact maternal well-being. This research paper aims to provide a comprehensive understanding of gastric issues experienced by pregnant women, focusing on their prevalence, contributing factors, and physiological mechanisms. A systematic review of literature was conducted to analyze existing studies on gastric problems during pregnancy. The review revealed that a high proportion of pregnant women experience gastric symptoms, including heartburn, acid reflux, nausea, constipation, and bloating, which can vary in severity across trimesters. Hormonal changes, increased intra-abdominal pressure, and altered gastrointestinal motility are key physiological factors contributing to these symptoms. The implications of gastric problems on maternal health and fetal development are discussed, emphasizing the importance of effective management strategies. Non-pharmacological approaches such as dietary modifications and lifestyle changes are highlighted, along with considerations for safe pharmacological interventions. This paper concludes by identifying future research directions aimed at improving the understanding and management of gastric problems in pregnancy, with implications for prenatal care and maternal health outcomes.

Introduction

During pregnancy, many women experience a range of gastric problems that can significantly impact their comfort and quality of life. These issues, including heartburn, acid reflux, nausea, constipation, and bloating, are common and often attributed to the physiological changes that occur in the body to support fetal development. Understanding the nature, causes, and implications of these gastric problems is crucial for optimizing maternal health and ensuring a positive pregnancy experience.

Correspondence

Nazmul MHM

poorpiku@yahoo.com

Figure 1 shows the changes in gastric anatomy during pregnancy.




Figure 1. Gastric anatomy A: before pregnancy, B: after pregnancy [1]

1. Overview of Gastric Problems in Pregnancy

Gastric problems during pregnancy encompass a spectrum of digestive discomforts that arise due to hormonal, mechanical, and physiological changes. One of the most prevalent issues is heartburn or acid reflux, characterized by a burning sensation in the chest and throat. This occurs when stomach acid flows back into the esophagus due to relaxation of the lower esophageal sphincter under the influence of pregnancy hormones like progesterone [2-9]. Nausea and vomiting, often referred to as morning sickness, affect a large proportion of pregnant women, particularly in the first trimester. The exact cause of morning sickness is multifactorial but is believed to involve hormonal fluctuations, altered gastric motility, and sensitivity to certain odors and foods.

Constipation is another common gastric problem in pregnancy, attributed to slowed gastrointestinal motility caused by elevated progesterone levels. This can lead to infrequent and hard stools, discomfort, and bloating.

Bloating and gas are also prevalent during pregnancy due to

reduced intestinal motility and increased intra-abdominal pressure from the growing uterus. This can contribute to feelings of fullness, discomfort, and abdominal distension.

2. Significance of Studying Gastric Issues During Pregnancy

Studying gastric problems during pregnancy is of paramount importance for several reasons. Firstly, these issues can significantly impact the quality of life and well-being of pregnant women. Severe gastric symptoms may lead to sleep disturbances, reduced dietary intake, and overall discomfort, potentially affecting maternal health outcomes.

Furthermore, certain gastric problems in pregnancy, such as severe nausea and vomiting (hyperemesis gravidarum), can lead to complications such as dehydration, electrolyte imbalances, and weight loss, necessitating medical intervention.

Understanding gastric problems during pregnancy is also critical for fetal health. Maternal nutrition and well-being directly influence fetal development, and persistent gastric issues may hinder adequate nutrient absorption and utilization, potentially impacting fetal growth and development.

3. Physiological Changes in the Digestive System During Pregnancy

Pregnancy induces profound changes in the digestive system to accommodate the growing fetus and support its nutritional needs. These changes are primarily mediated by hormonal fluctuations, particularly increased levels of progesterone and estrogen. Progesterone, known for its role in maintaining pregnancy, relaxes smooth muscle tissue throughout the body, including the gastrointestinal tract. This relaxation slows down digestive processes, leading to delayed gastric emptying and increased absorption of water from the colon, contributing to constipation. Elevated levels of estrogen also influence digestive function by promoting gallbladder contraction and increased bile production, which can contribute to gallstone formation and exacerbate symptoms of heartburn and indigestion [10-18]. Additionally, the expanding uterus exerts mechanical pressure on the stomach and intestines, displacing organs and further impeding normal digestion and motility. This anatomical shift can exacerbate symptoms of reflux, bloating, and discomfort.

Literature Review

Understanding the prevalence, types, and risk factors associated with gastric problems during pregnancy is essential for developing targeted interventions to improve maternal health outcomes. This literature review examines existing research on gastric problems experienced by pregnant women and identifies key factors contributing to these issues.

1. Prevalence of Gastric Problems Among Pregnant Women

Gastric problems are highly prevalent among pregnant women, affecting a significant proportion during different stages of pregnancy [2]. Studies indicate that up to 80% of pregnant women experience some form of gastrointestinal discomfort [3], with varying degrees of severity. Heartburn and acid reflux are among the most common complaints, reported by approximately 30% to 50% of pregnant women, particularly in the second and third trimesters [4,5]. Nausea and vomiting, often referred to as morning sickness, affect approximately 70% to 80% of pregnant women, predominantly in the first trimester. Constipation and bloating are also prevalent, affecting around 40% to 50% of

pregnant women due to hormonal and mechanical factors [19-27].

2. Types of Gastric Problems Experienced During Pregnancy

Heartburn and Acid Reflux:

Heartburn, characterized by a burning sensation in the chest and throat, occurs when stomach acid flows back into the esophagus. During pregnancy, hormonal changes, particularly increased levels of progesterone, relax the lower esophageal sphincter, contributing to reflux symptoms [6,7]. The growing uterus also displaces the stomach, further exacerbating reflux.

Nausea and Vomiting:

Nausea and vomiting are common during pregnancy, especially in the first trimester. While the exact cause is not fully understood, hormonal fluctuations (e.g., increased human chorionic gonadotropin), altered gastric motility, and sensitivity to certain odors and foods are implicated [8]. Severe cases of nausea and vomiting, such as hyperemesis gravidarum, require medical intervention to prevent dehydration and nutrient deficiencies.

Constipation and Hemorrhoids:

Constipation is a prevalent issue in pregnancy due to elevated levels of progesterone, which slow down intestinal motility and promote water absorption from the colon [9]. This results in infrequent and hard stools, discomfort, and bloating. Prolonged constipation can lead to hemorrhoids, swollen veins in the rectal area, further exacerbating discomfort and pain.

Bloating and Gas:

Increased intra-abdominal pressure from the growing uterus and hormonal influences on gastrointestinal motility contribute to bloating and gas during pregnancy [10]. Reduced intestinal motility leads to the accumulation of gas and discomfort, particularly in later stages of pregnancy.

3. Risk Factors for Gastric Issues During Pregnancy

Hormonal Changes:

Hormonal fluctuations, particularly increased levels of progesterone and estrogen, play a significant role in the development of gastric problems during pregnancy. Progesterone relaxes smooth muscle tone, including the lower esophageal sphincter and intestinal muscles, leading to reflux, constipation, and bloating [11]. Elevated estrogen levels influence gallbladder function and can exacerbate symptoms of heartburn and indigestion [28-33].

Mechanical Factors (Uterine Pressure):

The expanding uterus exerts mechanical pressure on the stomach and intestines, displacing organs and impairing normal digestive function. This pressure contributes to reflux symptoms, bloating, and discomfort, especially in the later stages of pregnancy [12].

Dietary and Lifestyle Factors:

Poor dietary choices, such as consuming spicy or fatty foods, and unhealthy lifestyle habits, such as smoking and excessive caffeine intake, can exacerbate gastric problems during pregnancy [13]. Inadequate hydration and lack of physical activity may also contribute to constipation and bloating [34-38].

Pathophysiology of Gastric Problems During Pregnancy

Gastric problems during pregnancy result from complex physiological changes affecting the digestive system. This section explores the underlying pathophysiology, focusing on hormonal influences, increased intra-abdominal pressure, and the specific roles of progesterone and relaxin.

1. Hormonal Influences on Digestive Function

Hormonal changes play a pivotal role in altering digestive function during pregnancy. Progesterone, significantly elevated during pregnancy, relaxes smooth muscle tissue, including the gastrointestinal tract. Progesterone causes relaxation of the lower esophageal sphincter (LES), leading to increased gastroesophageal reflux (GERD) and heartburn. Additionally, progesterone slows intestinal motility, contributing to delayed gastric emptying and constipation.

Elevated estrogen levels during pregnancy affect gallbladder function, reducing gallbladder motility and potentially leading to gallstone formation and indigestion.

2. Impact of Increased Intra-abdominal Pressure

As pregnancy progresses, the expanding uterus increases intra-abdominal pressure. This pressure affects the position and function of digestive organs, compressing the stomach and displacing it upward, contributing to reflux and heartburn.

Increased pressure on the intestines impairs peristalsis, leading to constipation and bloating.

3. Role of Progesterone and Relaxin in Gastrointestinal Symptoms

Relaxin, produced during pregnancy, relaxes smooth muscles, including those in the gastrointestinal tract. Relaxin slows peristalsis, exacerbating constipation, and may affect LES tone, worsening reflux and heartburn.

Progesterone reinforces smooth muscle relaxation in the gastrointestinal tract, contributing to delayed gastric emptying and increased susceptibility to reflux. Progesterone and relaxin collectively contribute to the spectrum of gastric problems experienced by pregnant women.

Understanding these physiological changes is crucial for developing effective management strategies to alleviate gastric symptoms during pregnancy [39-48].

Methods

This section outlines the research methodology employed to investigate gastric problems during pregnancy, including the systematic review of literature, analysis of clinical data, and utilization of surveys or questionnaires to gather relevant information.

1. Research Methodology Overview

The research methodology adopted for this study aimed to comprehensively examine the existing literature on gastric problems during pregnancy, analyze clinical data from relevant studies, and gather primary data through surveys or questionnaires administered to pregnant women.

2. Systematic Review of Literature

A systematic review of literature was conducted to identify and evaluate published studies related to gastric problems in pregnant women. Relevant databases such as PubMed, Embase, and Cochrane Library were systematically searched using specific keywords (e.g., "pregnancy," "gastric problems," "heartburn," "constipation") to retrieve relevant articles. Inclusion and exclusion criteria were defined to ensure the selection of high-quality studies that provided valuable insights into the prevalence, types, risk factors, and management of gastric issues during pregnancy.

The systematic review involved screening titles and abstracts, followed by full-text assessment of potentially relevant articles.

Data extraction was performed to capture key findings, including prevalence rates, associated factors, and physiological mechanisms underlying gastric problems in pregnancy. The quality of included studies was assessed using established criteria to ensure the reliability and validity of the synthesized evidence.

3. Analysis of Clinical Data

Clinical data from relevant studies, including observational studies and clinical trials, were analyzed to examine the incidence and severity of gastric problems among pregnant women. Data related to specific symptoms (e.g., heartburn, nausea, constipation), demographic characteristics (e.g., age, gestational age), and potential risk factors (e.g., hormonal changes, dietary habits) were extracted and synthesized. Statistical methods such as descriptive analysis, regression analysis, or meta-analysis were employed to derive meaningful conclusions from the pooled data and identify patterns or associations.

4. Surveys or Questionnaires Used

Primary data collection was facilitated through the administration of surveys or questionnaires to pregnant women attending prenatal clinics or maternity care centers. The survey instruments were designed based on validated scales or existing literature to capture information on the prevalence, severity, and impact of gastric problems during pregnancy. The questionnaire items covered a range of topics, including gastrointestinal symptoms experienced, dietary and lifestyle factors, coping strategies, and perceived effectiveness of interventions.

Surveys or questionnaires were distributed either in-person during prenatal visits or electronically through online platforms, ensuring confidentiality and voluntary participation. Data collection methods adhered to ethical guidelines, and informed consent was obtained from all participants prior to survey administration.

Findings

This section highlights key findings from research on gastric problems in pregnant women, revealing a high incidence of gastrointestinal symptoms during pregnancy. Heartburn and acid reflux affect 30% to 50% of pregnant women, particularly in the later trimesters, while nausea and vomiting are prevalent in 70% to 80% of women during the first trimester. Constipation and bloating also affect a significant proportion (40% to 50%) of pregnant women due to hormonal and mechanical factors associated with pregnancy. The severity of these symptoms varies widely among individuals, influenced by factors such as maternal age, gestational age, pre-existing gastrointestinal conditions, and dietary/lifestyle habits. Several factors contribute to the occurrence and intensity of gastric symptoms during pregnancy. Hormonal changes, including elevated levels of progesterone and estrogen, relax smooth muscle tone and disrupt gastrointestinal motility, leading to reflux, constipation, and bloating. Additionally, the expanding uterus exerts mechanical pressure on the stomach and intestines, exacerbating symptoms. Poor dietary choices and unhealthy lifestyle habits further worsen gastric symptoms, highlighting the importance of lifestyle modifications during pregnancy to alleviate these issues. Research also reveals trimester-specific variations in gastric problems during pregnancy. Nausea and vomiting (morning sickness) are most common in the first trimester, likely due to hormonal changes, particularly increased human chorionic gonadotropin (hCG) levels. Heartburn and acid reflux become more

prominent in the second trimester due to further relaxation of the lower esophageal sphincter (LES) and displacement of the stomach by the growing uterus. In the third trimester, symptoms may persist or worsen due to increased intra-abdominal pressure from the fully developed fetus, leading to persistent heartburn, constipation, and bloating.

Understanding the temporal patterns and factors influencing gastric symptoms across trimesters is crucial for developing tailored interventions and management strategies. By identifying the specific contributors to each phase of pregnancy-related gastric problems, healthcare providers can offer targeted support to alleviate symptoms and improve the overall well-being of pregnant women. Further research is needed to delve deeper into these patterns and factors, enabling more effective approaches to managing gastric issues during pregnancy and optimizing maternal health outcomes [49-56].

Discussion

The discussion critically interprets research findings on gastric problems during pregnancy, explores implications for maternal health and fetal development, and addresses challenges in diagnosing and managing these issues.

1. Interpretation of Research Findings

Research findings highlight the multifactorial nature of gastric problems in pregnancy, emphasizing hormonal changes, increased intra-abdominal pressure, and dietary/lifestyle factors impacting symptom occurrence and severity. These findings underscore the importance of holistic prenatal care addressing physiological and behavioral factors contributing to gastric symptoms.

Variations in prevalence and patterns across trimesters suggest dynamic physiological adaptations, emphasizing the need for tailored interventions by pregnancy stage. Individual differences in symptom presentation highlight the complexity of gastric issues, necessitating personalized care approaches.

2. Implications for Maternal Health and Fetal Development

Gastric problems during pregnancy can profoundly affect maternal health and fetal development. Persistent symptoms like severe reflux, vomiting, or constipation can lead to dehydration, electrolyte imbalances, and nutritional deficiencies, impacting maternal well-being and fetal growth.

Inadequate symptom management can contribute to maternal stress, sleep disturbances, and reduced quality of life. Prolonged reflux or nutritional deficiencies may affect fetal development, underscoring the need for early intervention and comprehensive management strategies to optimize outcomes for both mother and fetus.

3. Challenges in Diagnosing and Managing Gastric Issues During Pregnancy

Diagnosing and managing gastric problems in pregnancy pose unique challenges due to physiological changes and safety considerations:

- **Limited Treatment Options:** Some medications (e.g., proton pump inhibitors, antacids) require careful consideration during pregnancy due to fetal development risks.
- **Overlapping Symptoms:** Gastric symptoms overlap with normal pregnancy changes, complicating diagnosis and assessment.

- **Individual Variability:** Pregnant women respond differently to interventions, requiring personalized management approaches based on physiology and symptom causes.
- **Integrated Care:** Collaboration between obstetricians, gastroenterologists, and other providers is essential for comprehensive and effective management. Integrated care models considering maternal and fetal well-being are needed to address unique challenges posed by gastric symptoms in pregnancy.

Understanding these implications and challenges is crucial for optimizing prenatal care and improving outcomes for pregnant women experiencing gastric problems. Collaboration and personalized approaches are key to effective management and ensuring maternal-fetal health throughout pregnancy [57-60].

4. Management and Prevention

Effective management and prevention strategies for gastric problems during pregnancy focus on non-pharmacological approaches and safe pharmacological interventions tailored to optimize maternal comfort and fetal safety.

A. Non-pharmacological Approaches for Managing Gastric Problems

Dietary Modifications:

Encouraging pregnant women to adopt dietary modifications can alleviate gastric symptoms:

- Avoid spicy, fatty, and acidic foods that trigger reflux and heartburn.
- Eat smaller, more frequent meals to reduce gastric pressure and aid digestion.
- Consume fiber-rich foods (e.g., fruits, vegetables, whole grains) to prevent constipation.
- Stay hydrated by drinking adequate fluids throughout the day.

Lifestyle Changes:

Implementing lifestyle modifications can reduce gastric discomfort:

- Practice good posture, such as sitting upright during and after meals, to minimize reflux and intra-abdominal pressure.
- Engage in regular physical activity like walking or prenatal yoga to promote gastrointestinal motility.
- Avoid smoking and alcohol consumption, which exacerbate gastric symptoms and pose risks to fetal health.
- Elevate the head of the bed while sleeping to reduce nighttime reflux symptoms.

B. Pharmacological Interventions: Safety Considerations and Recommendations

When non-pharmacological measures are insufficient, pharmacological interventions may be considered under healthcare provider guidance, ensuring safety for both mother and fetus:

Antacids:

Antacids containing calcium carbonate or magnesium hydroxide offer short-term relief of heartburn and acid reflux during pregnancy. They neutralize stomach acid and alleviate symptoms.

H₂-Receptor Antagonists (H₂ Blockers):

Histamine-2 (H₂) receptor antagonists (e.g., ranitidine, famotidine) are safe for managing moderate to severe reflux symptoms during pregnancy. They reduce stomach acid production and provide longer-lasting relief compared to antacids.

Proton Pump Inhibitors (PPIs):

PPIs (e.g., omeprazole, pantoprazole) are reserved for severe reflux cases unresponsive to other treatments. They are recommended for

short-term use at the lowest effective dose due to potential risks to fetal development.

Safety Considerations and Recommendations:

Healthcare providers should assess risks and benefits of pharmacological interventions based on gestational age and maternal health status.

Pregnant women should be informed about potential medication risks and adhere to prescribed dosages and treatment durations. Regular monitoring and follow-up appointments are essential to evaluate treatment efficacy and ensure maternal and fetal well-being [61-63].

Future Research Directions

Identifying future research directions is imperative to enhance our understanding of gastric problems during pregnancy and to develop innovative therapeutic approaches for optimizing maternal health outcomes. Key areas for further investigation include mechanistic studies focusing on the specific hormonal influences, intra-abdominal pressure changes, and physiological adaptations that contribute to gastric symptoms during pregnancy. Additionally, research should explore the impact of maternal gastric problems on fetal development and long-term health outcomes, considering genetic predispositions and environmental factors that may influence susceptibility to these symptoms.

Longitudinal studies are essential for tracking the trajectory of gastric symptoms throughout pregnancy and beyond. These studies can reveal important temporal patterns, such as symptom evolution across trimesters and postpartum, identifying critical periods of vulnerability and variability. Moreover, longitudinal research can help identify predictive factors for severe gastric problems and associated complications during pregnancy, as well as investigate potential long-term consequences of untreated or inadequately managed gastric issues on maternal health and subsequent pregnancies. Such studies provide valuable insights that can inform personalized care plans and targeted interventions, ultimately optimizing maternal comfort and well-being.

Innovative therapeutic strategies are needed to address the complexities of gastric problems in pregnancy and enhance treatment efficacy and safety. This includes the development of novel pharmacological agents tailored for managing gastric symptoms with improved safety profiles during pregnancy. Precision medicine approaches based on genetic, hormonal, and physiological profiles can optimize treatment outcomes, while non-invasive interventions like acupuncture, biofeedback, or dietary supplements offer alternative options to alleviate symptoms and improve maternal comfort. Telemedicine and remote monitoring further enhance specialized care access for pregnant women experiencing gastric issues, demonstrating the potential of technology-driven solutions and interdisciplinary collaborations to drive innovation in prenatal care. Ongoing research in these areas will advance knowledge and refine management strategies, benefiting pregnant women worldwide by providing personalized, evidence-based interventions for gastric problems during pregnancy.

Conclusion

In conclusion, the research on gastric problems during pregnancy underscores their common occurrence and multifactorial nature, influenced by hormonal changes, increased intra-abdominal pressure, and dietary/lifestyle factors. These insights highlight the dynamic nature of gastric symptoms across trimesters, emphasizing the need for tailored management strategies throughout pregnancy. Effective approaches encompass both non-pharmacological interventions, such as dietary modifications and lifestyle adjustments, and safe pharmacological options when necessary to alleviate symptoms and optimize maternal comfort.

Addressing gastric problems in prenatal care is paramount for ensuring positive maternal and fetal outcomes. Untreated gastric symptoms can lead to complications like dehydration, nutrient deficiencies, and reduced quality of life for pregnant women, potentially impacting fetal development and long-term health risks. Early identification and appropriate management of gastric issues by healthcare providers can significantly improve maternal comfort, support optimal fetal growth, and enhance overall well-being during pregnancy.

To achieve these goals, healthcare providers should prioritize routine screening, education, and personalized counseling for pregnant women experiencing gastric symptoms. Collaborative efforts within multidisciplinary teams ensure comprehensive care and management tailored to individual needs. Expectant mothers are encouraged to adopt proactive measures such as maintaining a balanced diet, practicing good posture, and staying hydrated, while actively engaging with healthcare providers to address concerns and explore suitable treatment options. By fostering open communication and evidence-based interventions, healthcare providers and expectant mothers can effectively manage gastric problems during pregnancy, promoting maternal comfort and positive pregnancy experiences. Ongoing research and continuous efforts are vital to advancing our understanding and refining therapeutic strategies for gastric issues in pregnancy, ultimately benefiting pregnant women globally.

References

1. *Your Body throughout Pregnancy, Wondering about all the amazing (and sometimes weird) changes taking place in your body during pregnancy?*, <https://nationalpartnership.org/childbirthconnection/healthy-pregnancy/your-body-throughout-pregnancy/>
2. Baron, Todd H., Belinda Ramirez, and Joel E. Richter. "Gastrointestinal motility disorders during pregnancy." *Annals of internal medicine* 118.5 (1993): 366-375.
3. Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, Hazarika I, Das A. Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. *Toxicol Rep.* 2021; 8:376-385.
4. Thapa R, Afzal O, Gupta G, Bhat AA, Almalki WH, Alzarea SI, Kazmi I, Altamimi ASA, Subramaniyan V, Thangavelu L, Singh SK, Dua K. Unveiling the connection: Long-chain non-coding RNAs and critical signaling pathways in breast cancer. *Pathol Res Pract.*

- 2023; 249:154736.
5. Fuloria S, Subramaniyan V, Karupiah S, Kumari U, Sathasivam K, Meenakshi DU, Wu YS, Guad RM, Udupa K, Fuloria NK. A Comprehensive Review on Source, Types, Effects, Nanotechnology, Detection, and Therapeutic Management of Reactive Carbonyl Species Associated with Various Chronic Diseases. *Antioxidants (Basel)*. 2020;9(11):1075.
 6. Bhat AA, Thapa R, Goyal A, Subramaniyan V, Kumar D, Gupta S, Singh SK, Dua K, Gupta G. Curcumin-based nanoformulations as an emerging therapeutic strategy for inflammatory lung diseases. *Future Med Chem*. 2023;15(7):583-586.
 7. Malviya R, Raj S, Fuloria S, Subramaniyan V, Sathasivam K, Kumari U, Unnikrishnan Meenakshi D, Porwal O, Hari Kumar D, Singh A, Chakravarthi S, Kumar Fuloria N. Evaluation of Antitumor Efficacy of Chitosan-Tamarind Gum Polysaccharide Polyelectrolyte Complex Stabilized Nanoparticles of Simvastatin. *Int J Nanomedicine*. 2021;16:2533-2553.
 8. Chinnasamy V, Subramaniyan V, Chandiran S, Kayarohanam S, Kannian DC, Velaga VSSR, Muhammad S. Antiarthritic Activity of *Achyranthes Aspera* on Formaldehyde - Induced Arthritis in Rats. *Open Access Maced J Med Sci*. 2019;7(17):2709-2714.
 9. Bhat AA, Afzal O, Afzal M, Gupta G, Thapa R, Ali H, Hassan Almalki W, Kazmi I, Alzarea SI, Saleem S, Samuel VP, Gubbiyappa SK, Subramaniyan V. MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting. *Pathol Res Pract*. 2024;253:154991.
 10. Subramaniyan V, Shaik S, Bag A, Manavalan G, Chandiran S. Potential action of *Rumex vesicarius* (L.) against potassium dichromate and gentamicin induced nephrotoxicity in experimental rats. *Pak J Pharm Sci*. 2018;31(2):509-516.
 11. Sharma VK, Sharma PP, Mazumder B, Bhatnagar A, Subramaniyan V, Fuloria S, Fuloria NK. Mucoadhesive microspheres of glutaraldehyde crosslinked mucilage of Isabgol husk for sustained release of gliclazide. *J Biomater Sci Polym Ed*. 2021;32(11):1420-1449.
 12. Mukerjee N, Maitra S, Ghosh A, Subramaniyan V, Sharma R. Exosome-mediated PROTACs delivery to target viral infections. *Drug Dev Res*. 2023;84(6):1031-1036.
 13. Saminathan Kayarohanam, Vetrivelan Subramaniyan, Ashok Kumar Janakiraman, Madhan Kumar S. J. Antioxidant, Antidiabetic, and Antihyperlipidemic Activities of *Dolichandrone atrovirens* in Albino Wistar rats. *Research J. Pharm. and Tech*. 2019; 12(7): 3511-3516.
 14. Venkateshan S, Subramaniyan V, Chinnasamy V, Chandiran S. Anti-oxidant and anti-hyperlipidemic activity of *Hemidesmus indicus* in rats fed with high-fat diet. *Avicenna Journal of Phytomedicine*. 2016;6(5):516-25.
 15. Kumarasamy V, Anbazhagan D, Subramaniyan V, Vellasamy S. Blastocystis sp., Parasite Associated with Gastrointestinal Disorders: An Overview of its Pathogenesis, Immune Modulation and Therapeutic Strategies. *Curr Pharm Des*. 2018;24(27):3172-3175.
 16. Subasini U, Thenmozhi S, Sathyamurthy D, Vetrivelan S, Victor Rajamanickam G, Dubey GP. Pharmacognostic and phytochemical investigations of *Dioscorea bulbifera* L. *International Journal of Pharmacy & Life Sciences*. 2013;4(5).
 17. Vetrivelan S, Subasini U, Velmurugan C, Muthuramu T, Revathy J. Anti-inflammatory activity of *Cucumis sativus* seed in carrageenan and xylene induced edema model using albino wistar rats. *Int. J. Biopharm*. 2013;4(1):34-7.
 18. Huq MZ, Abdullah JY, Wong LS, Jamayet NB, Alam MK, Rashid QF, Husein A, Ahmad WM, Eusufzai SZ, Prasad S, Subramaniyan V. Clinical Applications of Artificial Intelligence and Machine Learning in Children with Cleft Lip and Palate-A Systematic Review. *International Journal of Environmental Research and Public Health*. 2022;19(17):10860.
 19. Puri A, Mohite P, Maitra S, Subramaniyan V, Kumarasamy V, Uti DE, Sayed AA, El-Demerdash FM, Algahtani M, El-kott AF, Shati AA. From nature to nanotechnology: The interplay of traditional medicine, green chemistry, and biogenic metallic phytonanoparticles in modern healthcare innovation and sustainability. *Biomedicine & Pharmacotherapy*. 2024;170:116083.
 20. De Rubis G, Paudel KR, Raju Allam VS, Malya V, Subramaniyan V, Singh SK, Panth N, Gupta G, Hansbro PM, Chellappan DK, Dua K. Involvement of osteopontin, EpCAM, estrogen receptor-alpha, and carbonic anhydrase IX protein in managing lung cancer via Berberine-loaded liquid crystalline nanoparticles. *Pathology-Research and Practice*. 2023.
 21. Prem P, Naveenkumar S, Kamaraj C, Ragavendran C, Priyadharsan A, Manimaran K, Alharbi NS, Rarokar N, Cherian T, Sugumar V, Thiruvengadam M. *Valeriana jatamansi* root extract a potent source for biosynthesis of silver nanoparticles and their biomedical applications, and photocatalytic decomposition. *Green Chemistry Letters and Reviews*. 2024;17(1):2305142.
 22. Naveenkumar S, Kamaraj C, Prem P, Raja RK,

- Priyadharsan A, Alrefaei AF, Govindarajan RK, Thamarai R, Subramaniyan V. Eco-friendly synthesis of palladium nanoparticles using *Zaleya decandra*: Assessing mosquito larvicidal activity, zebrafish embryo developmental toxicity, and impacts on freshwater sludge worm *Tubifex tubifex*. *Journal of Environmental Chemical Engineering*. 2024;12(2):111912.
23. Azad AK, Sulaiman WM, Almoustafa H, Dayoob M, Kumarasamy V, Subramaniyan V, Alshehri JM, Khan AA. A dataset of microstructure features of electrohydrodynamic assisted 5-fluorouracil-grafted alginate microbeads and physicochemical properties for effective colon targeted carriers drug delivery. *Data in Brief*. 2024:110202.
 24. Sharma A, Sharma C, Sharma L, Wal P, Mishra P, Sachdeva N, Yadav S, Vargas De-La Cruz C, Arora S, Subramaniyan V, Rawat R, Behl T, Nandave M. Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis. *Can J Physiol Pharmacol*. 2024. doi: 10.1139/cjpp-2023-0259. Epub ahead of print. PMID: 38334084.
 25. Gangwal A, Ansari A, Ahmad I, Azad AK, Kumarasamy V, Subramaniyan V, Wong LS. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities. *Frontiers in Pharmacology*. 2024;15:1331062.
 26. Mohite P, Yadav V, Pandhare R, Maitra S, Saleh FM, Saleem RM, Al-malky HS, Kumarasamy V, Subramaniyan V, Abdel-Daim MM, Uti DE. Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy. *ACS Omega*. 2024.
 27. Asif Ahmad Bhat, Gaurav Gupta, Rajiv Dahiya, Riya Thapa, Archana Gahtori, Moyad Shahwan, Vikas Jakhmola, Abhishek Tiwari, Mahish Kumar, Harish Dureja, Sachin Kumar Singh, Kamal Dua, Vinoth Kumarasamy, Vetriselvan Subramaniyan. *CircRNAs: Pivotal modulators of TGF- β signalling in cancer pathogenesis*. *Non-coding RNA Research*, 2024.
 28. Azad AK, Lai J, Sulaiman WM, Almoustafa H, Alshehade SA, Kumarasamy V, Subramaniyan V. The Fabrication of Polymer-Based Curcumin-Loaded Formulation as a Drug Delivery System: An Updated Review from 2017 to the Present. *cancer cells*. 2017;69:1290-9.
 29. Nag S, Mitra O, Tripathi G, Adur I, Mohanto S, Nama M, Samanta S, Gowda BH, Subramaniyan V, Sundararajan V, Kumarasamy V. Nanomaterials-assisted Photothermal Therapy for Breast Cancer: State-of-the Advances and Future Perspectives. *Photodiagnosis and Photodynamic Therapy*. 2024:103959.
 30. Dhar J, Hazra A, Patra R, Kumar V, Subramaniyan V, Kumarasamy V, Mitra A, Sayed A, Aleya L, El-Demerdash F, Almutairi M. Unveiling *Curvularia tuberculata*-induced leaf anomalies in *Rhododendron ferrugineum*: implications in cultural-ecological conservation and harnessing microbial intervention in socio-economic advancement. *Frontiers in Microbiology*. 2023;14.
 31. Al Quwatli L, Lee MF, Wu YS, Poh CL, Batumalaie K, Ahemad N, Fuloria NK, Fuloria S, Sekar M, Subramaniyan V, Sarke MR. Antiviral Activity of Withanolide A Against Different Infectivity Phases of Dengue Virus Serotype 2 in Vero Cell Line. *Revista Brasileira de Farmacognosia*. 2024:1-9.
 32. Alharbi HM, Alqahtani T, Alamri AH, Kumarasamy V, Subramaniyan V, Babu KS. Nanotechnological synergy of mangiferin and curcumin in modulating PI3K/Akt/mTOR pathway: a novel front in ovarian cancer precision therapeutics. *Frontiers in Pharmacology*. 2024;14:1276209.
 33. Mohamad Sobri WB, Naing NN, Wan-Arfah N, Abdullah S, Subramaniyan V, Wong LS, Selvaraj S. Prevalence and factors associated with excessive daytime sleepiness among Malaysian medical students. *Electron J Gen Med*. 2024; 21 (2): em571.
 34. Thapa R, Goyal A, Gupta G, Bhat AA, Singh SK, Subramaniyan V, Sharma S, Prasher P, Jakhmola V, Singh SK, Dua K. Recent developments in the role of protocatechuic acid in neurodegenerative disorders. *EXCLI journal*. 2023;22:595.
 35. Gupta G, Hussain MS, Thapa R, Dahiya R, Mahapatra DK, Bhat AA, Singla N, Subramaniyan V, Rawat S, Jakhmola V, Dua K. Hope on the horizon: Wharton's jelly mesenchymal stem cells in the fight against COVID-19. *Regenerative medicine*. 2023;18(9):675-8.
 36. Akash S, Baeza J, Mahmood S, Mukerjee N, Subramaniyan V, Islam MR, Gupta G, Rajakumari V, Chinni SV, Ramachawolran G, Saleh FM. Development of new drug candidate for the inhibition of Lassa virus glycoprotein and nucleoprotein by modification of Evodiamine as Promising Therapeutic Agents. *Frontiers in Microbiology*.;14:1206872.
 37. Rarokar NR, Saoji SD, Deole NV, Gaikwad M, Pandey A, Kamaraj C, Chinni SV, Subramaniyan V, Ramachawolran G, Dharashivkar S. Preparation and formula optimization of cephalixin loaded transferosomal gel by QbD to enhance the transdermal delivery: In vitro, ex vivo and in vivo study. *Journal of*

- Drug Delivery Science and Technology. 2023;89:104968.
38. Rizwi FA, Abubakar M, Puppala ER, Goyal A, Bhadravamy CV, Naidu VG, Roshan S, Tazneem B, Almalki WH, Subramaniyan V, Rawat S. Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer. *Journal of Environmental Pathology, Toxicology and Oncology*. 2023;42(4).
 39. Mujafarkani N, Ahamed FM, Babu KS, Debnath S, Sayed AA, Albadrani GM, Al-Ghadi MQ, Kumarasamy V, Subramaniyan V, Kamaraj C, Abdel-Daim MM. Unveiling a novel terpolymer-metal complex: A detailed exploration of synthesis, characterization, and its potential as an antimicrobial and antioxidant agent. *Heliyon*. 2023;9(10):e20459.
 40. Gholap AD, Gupta J, Kamandar P, Bhowmik DD, Rojekar S, Faiyazuddin M, Hatvate NT, Mohanto S, Ahmed MG, Subramaniyan V, Kumarasamy V. Harnessing nanovaccines for effective immunization— a special concern on COVID-19: facts, fidelity, and future prospective. *ACS biomaterials science & engineering*. 2023;10(1):271-97.
 41. Subramaniyan V, Lubau NS, Mukerjee N, Kumarasamy V. Alcohol-induced liver injury in signalling pathways and curcumin's therapeutic potential. *Toxicology Reports*. 2023;11:355-67.
 42. Mukherjee S, Nag S, Mukerjee N, Maitra S, Muthusamy R, Fuloria NK, Fuloria S, Adhikari MD, Anand K, Thorat N, Subramaniyan V. Unlocking exosome-based theragnostic signatures: deciphering secrets of ovarian cancer metastasis. *ACS omega*. 2023;8(40):36614-27.
 43. Kumarasamy V, Rajamanikam A, Anbazhagan D, Atroosh WM, Azzani M, Subramaniyan V, Abdullah SR. Systematic Review and Meta-Analysis: Epidemiology of Human Blastocystis spp. *Infection in Malaysia. Tropical Medicine and Infectious Disease*. 2023;8(8):415.
 44. Pandey A, Malviya R, Sundram S, Subramaniyan V. Issues and Challenges in Bioinformatics Tools for Clinical Trials. *Pharmaceutical industry 4.0: Future, Challenges & Application*. 2023:329.
 45. Janakiraman AK, Afroze S, Chew YL, Yee YJ, Zenli C, Subramaniyan V, Kayarohanam S. An Expedition Towards Formulating Natural Face Serum with *Garcinia mangostana* (Mangosteen). *Current Trends in Biotechnology and Pharmacy*. 2023;17(4A (Supplement)):61-9.
 46. Mukhopadhyay M, Mukherjee A, Subramaniyan V, Kumarasamy V, Sayed AA, El-Demerdash FM, Almutairi MH, Şuğan A, Dhara B, Mitra AK. Marvels of Bacilli in soil amendment for plant-growth promotion toward sustainable development having futuristic socio-economic implications. *Frontiers in microbiology*. 2023;14:1293302.
 47. Ansori AN, Pratama MR, Mukerjee N, Subramaniyan V, Ramachawolran G, Akash S, Baeza J, Mahmood S, Mukerjee N, Subramaniyan V, Islam MR. Arli Aditya Parikesit, Indonesia International Institute for Life-Sciences (iL), Indonesia. *Computational Drug Discovery for Emerging Viral Infections*. 2023:137.
 48. Kamaraj C, Naveenkumar S, Prem P, Ragavendran C, Subramaniyan V, Al-Ghanim KA, Malafaia G, Nicoletti M, Govindarajan M. Green synthesis and biophysical characterization of silver and palladium nanoparticles using *Laureliopsis philippiana*: A potent eco-friendly larvicide with negligible impact on zebrafish (*Danio rerio*). *Journal of Asia-Pacific Entomology*. 2023;26(4):102164.
 49. Santhoshkumar T, Govindarajan RK, Kamaraj C, Alharbi NS, Manimaran K, Yanto DH, Subramaniyan V, Baek KH. Biological synthesis of nickel nanoparticles using extracellular metabolites of *Bacillus Sphaericus*: Characterization and vector-borne disease control applications. *South African Journal of Botany*. 2023;162:481-94.
 50. Wan-Arfah N, Muzaimi M, Naing NN, Subramaniyan V, Wong LS, Selvaraj S. Prognostic factors of first-ever stroke patients in suburban Malaysia by comparing regression models. *Electron J Gen Med*. 2023; 20 (6): em545.
 51. Bharadwaj KK, Rabha B, Ahmad I, Mathew SP, Bhattacharjee CK, Jaganathan BG, Poddar S, Patel H, Subramaniyan V, Chinni SV, Ramachawolran G. Rhamnetin, a nutraceutical flavonoid arrests cell cycle progression of human ovarian cancer (SKOV3) cells by inhibiting the histone deacetylase 2 protein. *Journal of Biomolecular Structure and Dynamics*. 2023:1-6.
 52. Singh AK, Malviya R, Sundram S, Subramaniyan V. Big data in oncology: Extracting knowledge from machine learning. *In Big Data in Oncology: Impact, Challenges, and Risk Assessment 2023* (pp. 77-104). River Publishers.
 53. Singla M, Verma S, Thakur K, Goyal A, Sharma V, Sharma D, Porwal O, Subramaniyan V, Behl T, Singh SK, Dua K. From Plants to Therapies: Exploring the Pharmacology of Coumestrol for Neurological Conditions. *Current medicinal chemistry*. 2024.
 54. Alhussiney K, Othman R, Wei C, Abdullah I, Subramaniyan V. *In silico* Discovery of R1OK3 Inhibitors

-
- Against Pancreatic Ductal Adenocarcinoma via Molecular Docking, Molecular Dynamics Simulations, and ADMET Prediction. Malaysian Journal of Medicine & Health Sciences. 2024 Jan 3;20.*
55. Debnath S, Elgorban AM, Bahkali AH, Eswaramoorthy R, Verma M, Syed A, Subramaniyan V, Kamaraj C, Wong LS, Kumarasamy V. Enhancing drought tolerance in cauliflower (*Brassica oleracea* var. *botrytis*) by targeting *LFY* transcription factor modulation via the ethylene precursor, *ACCA*: an innovative computational approach. *Frontiers in Plant Science. 2024 Feb 28;15:1255979.*
56. Amin Z, Alkhatabi HA, Subramaniyan V, Alreemi RM, Husn M, Fayaz W, Thatsananchalee P, Khalid A, Shah SA, Wadood A. Therapeutic Potential of 6-Amino Flavone: A Novel Approach for Diabetes and Inflammation via *TNF- α /p-IRS* Signaling Pathway in Albino Mice.
57. Lai J, Azad AK, Sulaiman WM, Kumarasamy V, Subramaniyan V, Alshehade SA. Alginate-Based Encapsulation Fabrication Technique for Drug Delivery: An Updated Review of Particle Type, Formulation Technique, Pharmaceutical Ingredient, and Targeted Delivery System. *Pharmaceutics. 2024 Mar 6;16(3):370.*
58. Subramaniyan V. Therapeutic importance of castor seed oil. In *Nuts and Seeds in Health and Disease Prevention 2020 Jan 1* (pp. 485-495). Academic Press.
59. Rani S, Sharma U, Deshmukh MP, Kumar V, Sharma KC, Malik MK, Subramaniyan V. Immunomodulatory and Antioxidant Potential of Polyherbal *Dhatryadi Rasayana* in the Form of *Churna* and *Granules*. *ACS Omega. 2024 Mar 19;9(13):14781-90.*
60. Dh HS, Sultana R, Prabhu A, Pavan SR, Mohanto S, Subramaniyan V. Biomedicine and pharmacotherapeutic effectiveness of combinatorial atorvastatin and quercetin on diabetic nephropathy: An *in vitro* study. *Biomedicine & pharmacotherapy= Biomedecine & pharmacotherapie.;174:116533.*
61. Bharadwaj KK, Rabha B, Ahmad I, Mathew SP, Bhattacharjee CK, Jaganathan BG, Poddar S, Patel H, Subramaniyan V, Chinni SV, Ramachawolran G. Rhamnetin, a nutraceutical flavonoid arrests cell cycle progression of human ovarian cancer (SKOV3) cells by inhibiting the histone deacetylase 2 protein. *Journal of biomolecular structure & dynamics.:1-6.*
62. Subramaniyan V. Therapeutic Importance of Castor Seed Oil. In *Nuts and Seeds in Health and Disease Prevention 2020* (pp. 485-495). Academic Press.
63. Derbyshire, Emma, et al. "Diet, physical inactivity and the prevalence of constipation throughout and after pregnancy." *Maternal & child nutrition 2.3* (2006): 127-134.